Eris Lifesciences reappoints Sujesh Vasudevan as independent director

scanx
Reviewed by
Ashish TScanX News Team
Key Highlights
  • Eris Lifesciences reappointed Sujesh Vasudevan as Independent Director for five years
  • New term commences July 25, 2027, and ends July 24, 2032
  • Board scheduled the 20th AGM for September 25, 2026
  • Decisions approved during the August 31, 2026 board meeting
powered bylight_fuzz_icon
49700999

*this image is generated using AI for illustrative purposes only.

Eris Lifesciences has approved the re-appointment of Mr. Sujesh Vasudevan as an Independent Director for a five-year term. The Board also scheduled the company’s 20th Annual General Meeting for September 25, 2026.

The decisions were taken during a Board meeting held on August 31, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Approvals

Based on the recommendation of the Nomination & Remuneration Committee, the Board recommended Mr. Vasudevan’s re-appointment to shareholders. His new tenure is set to commence on July 25, 2027, and will run until July 24, 2032.

The Board also convened the 20th Annual General Meeting of members. The meeting is scheduled to take place on Friday, September 25, 2026.

Meeting Details

The Board of Directors meeting began at 10:30 am and concluded at 11:00 am. Milind Talegaonkar, Company Secretary & Compliance Officer, certified the disclosures.

Historical Stock Returns for Eris Lifesciences

1 Day5 Days1 Month6 Months1 Year5 Years
-0.80%-1.80%-6.22%-3.98%-27.24%0.0%

How might Mr. Vasudevan's continued leadership as an Independent Director influence Eris Lifesciences' strategic direction in the generic and specialty pharmaceuticals sectors?

What specific governance or compliance initiatives are shareholders likely to prioritize for discussion at the 20th Annual General Meeting in September 2026?

Could the re-appointment signal stability in the boardroom that positively impacts investor confidence ahead of the company's upcoming financial reporting cycles?

Eris Lifesciences schedules analyst meet with HBM Partners on August 27

scanx
Reviewed by
Shriram SScanX News Team
Key Highlights
  • Eris Lifesciences holds investor meet on August 27 at 10:30 am
  • Counterparty is HBM Partners AG for a 1x1 session
  • Mr. Amit Bakshi represents management
  • No unpublished price sensitive information to be shared
powered bylight_fuzz_icon
49116889

*this image is generated using AI for illustrative purposes only.

Eris Lifesciences has scheduled a meeting with analysts and investors on August 27 at 10:30 am. The session will be a one-on-one interaction with HBM Partners AG.

Meeting details

The company has announced the upcoming interaction with the investment community. The session is set to bring together analysts and investors for a direct engagement with the company. Mr. Amit Bakshi will represent the management during the in-person meeting.

Parameter Details
Event Analyst and investor meeting
Date August 27
Time 10:30 am
Counterparty HBM Partners AG
Mode In Person (1x1)

The schedule is indicative and subject to change. The company stated that no unpublished price sensitive information will be discussed.

Historical Stock Returns for Eris Lifesciences

1 Day5 Days1 Month6 Months1 Year5 Years
-0.80%-1.80%-6.22%-3.98%-27.24%0.0%

What specific strategic initiatives or pipeline updates might Eris Lifesciences highlight to HBM Partners AG during this one-on-one session?

How could the insights shared with HBM Partners AG influence broader market sentiment or analyst ratings for Eris Lifesciences in the coming quarter?

Are there any recent regulatory approvals or commercial milestones that might be the primary focus of this upcoming investor interaction?

More News on Eris Lifesciences

1 Year Returns:-27.24%